Slide 1: Diagnostics Biotech Company
Diagnostics Biotech Company NASDAQ: PRPO Founded in 2011 HQ: New Haven, CT DISCLAIM ER T HIS PRESENT AT ION HAS BEE N PREPARE D B Y P RE CIPIO IN C. (T HE “C O MPAN Y”) AND IS GENERA L BA CKGROUND IN FOR MAT I ON ABOUT T HE C O MPAN Y’S ACT IV IT IES AS O F T HE DAT E O F T HIS PRESENT AT ION . B Y
Slide 2: We develop products that save lives
We develop products that save lives 2 Acute Myeloid Leukemia (AML) is one of the deadliest forms of cancer. Physicians treating patients with AML face two unsuitable options. Precipio’s assay enables immediate, targeted treatment - SAVING LIVES Patient diagnosed with AML Molecular tests ordered (10-
Slide 3: Precipio is eliminating ineffective diagnosis
3 Precipio is eliminating ineffective diagnosis We eliminate both misdiagnosis and diagnostic delays, where outcomes depend on speed and accuracy. of blood cancer diagnoses are incorrect 25-40%* diagnostic errors cost US healthcare annually 10+ $100B** days generally accepted industry turnaround tim
Slide 4: We've built an innovative product development platform, creating an unfair advantage
We’ve built an innovative product development platform, creating an unfair advantage Our Unfair Advantage We are the first customer of every product we develop Our hands-on experience is translated to our customers We develop products in a rapid, cost-effective manner Pathology Service Lab Facilitie
Slide 5: Our profitable clinical lab business fully funds R&D, significantly de-risking the company
Our profitable clinical lab business fully funds R&D, significantly de-risking the company ▪ Identifies market needs ▪ Provides infrastructure and patient samples R&D Platform Clinical Lab ▪ Leverages infrastructure & samples for rapid product development Example: Precipio’s BCR-ABL1 assay 1. Most a
Slide 6: We deliver testing options not available before
6 We deliver testing options not available before Our products address the key challenges laboratories face: Staff shortage, Capital budgets, and the ability to deliver timely results Factor Competition Precipio Solution Impact Workflow Complex Simple Simplified workflow enables streamlined process,
Slide 7: We scale through national distribution partner agreements already in place
We scale through national distribution partner agreements already in place Go-to-market efficiency through leading channel partners, with nationwide reach 7 POL* Hospital / Academic Reference Lab * Physician-Owned Laboratory
Slide 8: Blood cancers are just the beginning: Expanding into a $40B+ market
Blood cancers are just the beginning: Expanding into a $40B+ market * Transparency Market Research Onco-Hematology Molecular Market Testing June 2023 ** BioSpace Molecular Diagnostic Market Size Report Aug 2024 Our technology is platform-ready to expand beyond hematology into broader cancer and mole
Slide 9: Recurring revenue growth, high-margin outlook
Recurring revenue growth, high-margin outlook 0% 20% 40% 60% 80% 100% Current Short term Long term Revenue mix Products Path services 0% 20% 40% 60% 80% 100% Current Short term Long term Path Services Products Blended Gross Margin Analysis As we scale products and alter the revenue mix, gross margin
Slide 10: Proven leadership with deep clinical and commercial experience
Proven leadership with deep clinical and commercial experience Ilan Danieli CEO Ilan Danieli CEO Dr. Ayman Mohamed CTO Dr. Ayman Mohamed CTO Zaki Sabet COO Zaki Sabet COO Miri Radomski CPO Legal Counsel Miri Radomski CPO & Legal Counsel Stephen Miller CCO Stephen Miller CCO Matt Gage CFO Matt Gage C
Slide 11: Precipio: A high-margin, proprietary diagnostics platform with massive upside
Precipio: A high-margin, proprietary diagnostics platform with massive upside Disruptive, Proprietary Products Rooted in solutions to real-world diagnostic and monitoring challenges 1 Unique Development Platform - rapid and capital efficient 2 3 Massive Market Opportunity – growing from $0.5B TAM to
Slide 12: Thank you.
Thank you. Please contact us at investors@precipiodx.com 20250817